Skip to main content
Clinical Trials/ACTRN12621000006842
ACTRN12621000006842
Recruiting
未知

A Comparison of Gut Microbiome Profiles in Relation to Cognition and Neuroplasticity across Ageing and Parkinson’s disease

Helen Macpherson0 sites144 target enrollmentJanuary 8, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Parkinson's disease
Sponsor
Helen Macpherson
Enrollment
144
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 8, 2021
End Date
TBD
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Helen Macpherson

Eligibility Criteria

Inclusion Criteria

  • 50\-80 years for both groups (Healthy older and PD groups) and between 18\-35 years for the healthy younger adult group
  • Presence of PD, as determined through independent neurologist, for PD group. Level of severity (UPDRS stage II and III) will be determined and mild\-moderate PD patients will be included. Note: No early onset PD cases to be included in the study, PD diagnosis has to have occurred at 50 years of age or later.
  • For healthy older group, no neurological conditions present and no first\-degree relatives with PD (determined through self\-report questionnaires). No signs of Parkinsonism or symptoms associated with premotor PD (Assessed through the Unified Parkinson’s Disease Rating Scale (UPDRS stages II and III)
  • greater than or equal to 24/30 for the healthy older group on the Montreal Cognitive Assessment (MoCA), greater than or equal to 21 for the PD group on the MoCA
  • For the healthy younger adult group:
  • Aged between 18\-35 years
  • No neurological/neurodegenerative conditions and no first\-degree relatives with PD (determined through self\-report questionnaires)
  • No signs of Parkinsonism or symptoms associated with premotor PD (Assessed through the Unified Parkinson’s Disease Rating Scale (UPDRS stages II and III)
  • greater than or equal to 24/30 on the MoCA

Exclusion Criteria

  • Taken prebiotics (fibre supplementation, inulin etc.) or probiotics (Over the counter probiotics, , including Yakult or similar products) within previous 3 months
  • Gastrointestinal diseases such as Colitis or Crohn’s disease
  • Obesity (BMI greater or equal to 30\)
  • Drugs/Medication including proton\-pump inhibitors and antibiotic use (within the previous 3 months)
  • Current drug or alcohol abuse
  • Conditions precluding TMS (epilepsy, pacemakers, metal implants etc.)
  • PD individuals excluded if they have atypical or secondary Parkinsonism. Additional neurological conditions (i.e. stroke, epilepsy etc. will also be exclusions)
  • Clinical diagnosis of depression, or a score of greater than 21 (21\-30 indicates moderate depression) as assessed through Beck’s Depression Inventory

Outcomes

Primary Outcomes

Not specified

Similar Trials